APA ציטוט

Doi, T., Ohtsu, A., Fuse, N., Yoshino, T., Tahara, M., Shibayama, K., . . . Weinreich, D. M. (2012). Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors. Springer-Verlag.

Citação norma Chicago

Doi, Toshihiko, Atsushi Ohtsu, Nozomu Fuse, Takayuki Yoshino, Makoto Tahara, Kazuhiro Shibayama, Takatoshi Takubo, and David M. Weinreich. Phase 1 Study of Trebananib (AMG 386), an Angiogenesis Targeting Angiopoietin-1/2 Antagonist, in Japanese Patients With Advanced Solid Tumors. Springer-Verlag, 2012.

ציטוט MLA

Doi, Toshihiko, et al. Phase 1 Study of Trebananib (AMG 386), an Angiogenesis Targeting Angiopoietin-1/2 Antagonist, in Japanese Patients With Advanced Solid Tumors. Springer-Verlag, 2012.